Literature DB >> 20609950

Erythropoietin: not just about erythropoiesis.

Pietro Ghezzi, Myrian Bernaudin, Myriam Bernaudinb, Roberto Bianchi, Roberto Bianchic, Klas Blomgren, Michael Brines, Wendy Campana, Guido Cavaletti, Anthony Cerami, Michael Chopp, Thomas Coleman, Murat Digicaylioglu, Hannelore Ehrenreich, Serhat Erbayraktar, Zebeide Erbayraktar, Max Gassmann, Sermin Genc, Necati Gokmen, Giovanni Grasso, Sandra Juul, Stuart A Lipton, Carla Cerami Hand, Roberto Latini, Giuseppe Lauria, Marcel Leist, Samuel Sathyanesan Newton, Edwige Petit, Lesley Probert, Alessandra Sfacteria, Anna-Leena Siren, Mark Talan, Chris Thiemermann, Daan Westenbrink, Magdi Yaqoob, Changlian Zhu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20609950      PMCID： PMC4894326          DOI： 10.1016/S0140-6736(10)60992-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

Authors:  M L Brines; P Ghezzi; S Keenan; D Agnello; N C de Lanerolle; C Cerami; L M Itri; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

2.  Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells.

Authors:  Angus M Sinclair; Angela Coxon; Ian McCaffery; Stephen Kaufman; Katherine Paweletz; Liqin Liu; Leigh Busse; Susan Swift; Steven Elliott; C Glenn Begley
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

3.  Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.

Authors:  Vinni Juneja; Patricia Keegan; Joseph E Gootenberg; Mark D Rothmann; Yuan Li Shen; Kyung Y Lee; Karen D Weiss; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 4.  A systematic review and meta-analysis of erythropoietin in experimental stroke.

Authors:  Mikael Jerndal; Kalle Forsberg; Emily S Sena; Malcolm R Macleod; Victoria E O'Collins; Thomas Linden; Michael Nilsson; David W Howells
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-30       Impact factor: 6.200

Review 5.  The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis.

Authors:  Jens Minnerup; Jan Heidrich; Andreas Rogalewski; Wolf-Rüdiger Schäbitz; Jürgen Wellmann
Journal:  Stroke       Date:  2009-06-18       Impact factor: 7.914
  5 in total
  18 in total

1.  Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke.

Authors:  Manuela Mengozzi; Ilaria Cervellini; Pia Villa; Zübeyde Erbayraktar; Necati Gökmen; Osman Yilmaz; Serhat Erbayraktar; Mathini Manohasandra; Paul Van Hummelen; Peter Vandenabeele; Yuti Chernajovsky; Alexander Annenkov; Pietro Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 2.  Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models.

Authors:  Johannes Vogel; Max Gassmann
Journal:  J Physiol       Date:  2011-01-31       Impact factor: 5.182

3.  Erythropoietin in the neurology ICU.

Authors:  Claudia Robertson; Saeed Sadrameli
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

4.  The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways.

Authors:  Jan Hendrik Duedal Rölfing; Anette Baatrup; Maik Stiehler; Jonas Jensen; Helle Lysdahl; Cody Bünger
Journal:  Stem Cell Rev Rep       Date:  2014-02       Impact factor: 5.739

5.  Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  J Neurochem       Date:  2014-08-06       Impact factor: 5.372

6.  Erythropoietin (EPO) increases myelin gene expression in CG4 oligodendrocyte cells through the classical EPO receptor.

Authors:  Ilaria Cervellini; Alexander Annenkov; Thomas Brenton; Yuti Chernajovsky; Pietro Ghezzi; Manuela Mengozzi
Journal:  Mol Med       Date:  2013-08-28       Impact factor: 6.354

7.  Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.

Authors:  Nimesh S A Patel; Hannah L Kerr-Peterson; Michael Brines; Massimo Collino; Mara Rogazzo; Roberto Fantozzi; Elizabeth G Wood; Florence L Johnson; Muhammad M Yaqoob; Anthony Cerami; Christoph Thiemermann
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

8.  The role of erythropoietin in remote renal preconditioning on hippocampus ischemia/reperfusion injury.

Authors:  Mehdi Khaksari; Fatemeh Zare Mehrjerdi; Mohammad Ebrahim Rezvani; Fatemeh Safari; Aghdas Mirgalili; Somayeh Niknazar
Journal:  J Physiol Sci       Date:  2016-04-20       Impact factor: 2.781

9.  Widespread Expression of Erythropoietin Receptor in Brain and Its Induction by Injury.

Authors:  Christoph Ott; Henrik Martens; Imam Hassouna; Bárbara Oliveira; Christian Erck; Maria-Patapia Zafeiriou; Ulla-Kaisa Peteri; Dörte Hesse; Simone Gerhart; Bekir Altas; Tekla Kolbow; Herbert Stadler; Hiroshi Kawabe; Wolfram-Hubertus Zimmermann; Klaus-Armin Nave; Walter Schulz-Schaeffer; Olaf Jahn; Hannelore Ehrenreich
Journal:  Mol Med       Date:  2015-09-01       Impact factor: 6.354

10.  Erythropoietin in the critically ill: do we ask the right questions?

Authors:  Oscar McCook; Michael Georgieff; Angelika Scheuerle; Peter Möller; Christoph Thiemermann; Peter Radermacher
Journal:  Crit Care       Date:  2012-09-26       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.